Takeda Pharmaceutical Co. is exploring a deal to sell several of its over-the-counter and prescription drugs in emerging markets and Western Europe, The Japan Times reports.
What you should know:
1. Takeda would likely sell the drugs it acquired when it purchased Nycomed in 2011. That drug portfolio could fetch about $3 billion.
2. People familiar with the matter listed Acino International AG, Avista Capital Partners, Stada Arzneimittel AG, EMS SA and Uniao Quimica Farmaceutica Nacional as potential buyers in emerging markets.
3. Takeda is also exploring deals in Western Europe with Advent International, Apollo Global Management and Cerberus Capital Management. The potential saleable assets in this deal are valued at $1.1 billion.
4. Takeda became one of the most indebted drugmakers in the world when it acquired Shire in January.